Bridget Wagner has been devoted to modulating phenotypes relevant to diabetes (e.g., beta-cell regeneration, mitochondrial biology in muscle) with small molecules. She is focused on the discovery of small molecules capable of increasing the number of beta cells in culture, with the ultimate goal of identifying candidate compounds for developing therapies for diabetes. This work involves the use of cell-based screening and analytical techniques that she has developed and used in over fifteen years of experience in small-molecule discovery.